Xuming Chen

Xuming Chen

Auto-generated profile, based on publicly available information

Xuming Chen

Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
XCXuming Chen
Xuming Chen
SSShanlin Sun
Shanlin Sun
NBNarisu Bai
Narisu Bai
KHKun Han
Kun Han
QLQianqian Liu
Qianqian Liu
YLYong Liu
Yong Liu
Delineating organs at risk (OARs) on computed tomography (CT) images is an essential step in radiation therapy; however, it is notoriously time-consuming and prone to inter-observer variation. Herein, we report a deep learning-based automatic segmentation (AS) algorithm (WBNet) that can accurately and efficiently delineate all major OARs in the entire body directly on CT scans. We collected 755 CT scans of the head and neck, thorax, abdomen, and pelvis and manually delineated 50 OARs on the CT images. The CT images with contours were split into training and test sets consisting of 505 and 250 cases, respectively, to develop and validate WBNet. The volumetric Dice similarity coefficient (DSC) and 95th-percentile Hausdorff distance (95% HD) were calculated to evaluate delineation quality for each OAR. We compared the performance of WBNet with three AS algorithms: one commercial multi-atlas-based automatic segmentation (ABAS) software, and two deep learning-based AS algorithms, namely, AnatomyNet and nnU-Net. We have also evaluated the time saving and dose accuracy of WBNet. WBNet achieved average DSCs of 0.84 and 0.81 on in-house and public datasets, respectively, which outperformed ABAS, AnatomyNet, and nnU-Net. WBNet could reduce the delineation time significantly and perform well in treatment planning, with clinically acceptable dose differences compared with those in manual delineation. This study shows the feasibility and benefits of using WBNet in clinical practice.

1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YXYiqing Xu
Yiqing Xu
WTWenzhi Tu
Wenzhi Tu
DSDi Sun
Di Sun
XCXuming Chen
Xuming Chen
YGYulong Ge
Yulong Ge
YLYong Liu
Yong Liu

1 January 2021
Verified
Conference Paper
Open access
HTHao Tang
Hao Tang
XLXingwei Liu
Xingwei Liu
KHKun Han
Kun Han
XXXiaohui Xie
Xiaohui Xie
XCXuming Chen
Xuming Chen
NBNarisu Bai
Narisu Bai
Multi-organ segmentation is one of most successful applications of deep learning in medical image analysis. Deep convolutional neural nets (CNNs) have shown great promise in achieving clinically applicable image segmentation performance on CT or MRI images. State-of-the-art CNN segmentation models apply either 2D or 3D convolutions on input images, with pros and cons associated with each method: 2D convolution is fast, less memory-intensive but inadequate for extracting 3D contextual information from volumetric images, while the opposite is true for 3D convolution. To fit a 3D CNN model on CT or MRI images on commodity GPUs, one usually has to either downsample input images or use cropped local regions as inputs, which limits the utility of 3D models for multi-organ segmentation. In this work, we propose a new framework for combining 3D and 2D models, in which the segmentation is realized through high-resolution 2D convolutions, but guided by spatial contextual information extracted from a low-resolution 3D model. We implement a self-attention mechanism to control which 3D features should be used to guide 2D segmentation. Our model is light on memory usage but fully equipped to take 3D contextual information into account. Experiments on multiple organ segmentation datasets demonstrate that by taking advantage of both 2D and 3D models, our method is consistently outperforms existing 2D and 3D models in organ segmentation accuracy, while being able to directly take raw whole-volume image data as inputs.

1 July 2018 in American Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YLYong Liu
Yong Liu
GZGuoqi Zhao
Guoqi Zhao
YXYi Xu
Yi Xu
TZTiening Zhang
Tiening Zhang
ZCZhixiao Chen
Zhixiao Chen
TCTingfeng Chen
Tingfeng Chen
The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. Therefore, a more efficacious and safer regimen is urgently needed. Patients with R0 resected gastric carcinoma received up to two 21-day cycles of postoperative adjuvant preradiation and postradiation DCF chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1 to 3, and a continuous infusion of fluorouracil 750 mg/m2 on days 1 to 5), respectively. Chemoradiotherapy between preradiation and postradiation chemotherapy was initiated on day 43 and consisted of intensity-modulated radiotherapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 5 weeks. A total of 55 patients were evaluated and 76% (42) of patients completed the prescribed therapy. With a median follow-up of 61 months, the 3- and 5-year progression-free survival rates were 67% (95% confidence interval [CI], 54%-80%) and 59% (95% CI, 46%-72%), respectively; and the 3- and 5-year overall survival rates were 72% (95% CI, 60%-84%) and 61% (95% CI, 48%-74%), respectively. The most common grade 3 or greater toxicity, during the chemotherapy phase, was neutropenia (24%). Common grade 3/4 toxicities during concurrent chemoradiotherapy were nausea (32%), vomiting (26%), fatigue (15%), and anorexia (19%). These results demonstrate that this adjuvant regimen is active with an acceptable toxicity profile. A randomized phase 3 trial comparing the Intergroup 0116 chemoradiotherapy regimen with this regimen is underway. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

29 September 2025 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
NCNingning Cheng
Ningning Cheng
ZCZhixiao Chen
Zhixiao Chen
YCYing Chen
Ying Chen
YHYe Hu
Ye Hu
ZWZijie Wang
Zijie Wang
TCTingfeng Chen
Tingfeng Chen